期刊
NEUROIMMUNOMODULATION
卷 15, 期 1, 页码 19-28出版社
KARGER
DOI: 10.1159/000135620
关键词
glucocorticoids; glucocorticoid resistance; corticosteroid binding globulin; multidrug resistance transporter; 11 beta-hydroxysteroid dehydrogenase; glucocorticoid receptor; cytokines; inflammation; autoimmune disease
资金
- NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002585] Funding Source: NIH RePORTER
- Intramural NIH HHS [ZIA MH002585-19, Z01 MH002585-17] Funding Source: Medline
Rheumatoid arthritis ( RA) is characterized by chronic inflammation of the synovial membrane, leading to joint destruction. Many autoimmune diseases and disease states of chronic inflammation are accompanied by alterations in the complex interactions between the endocrine, nervous and immune systems. Glucocorticoids, an end product of the hypothalamic-pituitary-adrenal axis, are a mainstay treatment for many autoimmune diseases, including RA, because of their potent anti-inflammatory action. However, about 30% of patients with RA fail to respond to steroid therapy. There are various mechanisms that may contribute to the development of glucocorticoid resistance in inflammatory disorders, which will be the subject of this review. In addition, glucocorticoid resistance may be a contributing factor in the development of inflammatory/autoimmune diseases themselves. Therefore, further elucidation of these mechanisms will reveal new targets for therapeutic intervention in the treatment of RA. Copyright (C) 2008 S. Karger AG, Basel.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据